Mayte Gil-Candel

8PUBLICATIONS
17CO-AUTHORS
NanomedicineImmunogenetics (incl. genetic immunology)Digital healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 30, 2025
Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia.

Antonio Solana-Altabella, Carles Iniesta-Navalón, Maria Chovi-Trull

|Feb 26, 2025
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Octavio Ballesta-López, Mayte Gil-Candel, María Centelles-Oria

|Apr 21, 2022
Developing a telepharmacy programme with home medication dispensing and informed delivery in a tertiary hospital: description of the model and analysis of the results.

Mayte Gil-Candel, Antonio Solana-Altabella, Esther Vicente-Escrig

|Jan 25, 2021
Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival.

Carles Iniesta Navalón, Maite Gil Candel, Ignacio Salar Valverde

|Nov 20, 2020
Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.

Rosa Gómez Espín, Isabel Nicolás De Prado, Mayte Gil Candel

|Jul 21, 2020
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.

Mayte Gil Candel, Juan José Gascón Cánovas, Rosa Gómez Espín

Pageof 2

Frequent Collaborators

5 joint publications

Carles Iniesta-Navalón

3 joint publications

Antonio Solana-Altabella

2 joint publications

Juan Eduardo Megías-Vericat

2 joint publications

José Luis Poveda-Andrés